Tech Q&A with CARE Research

February 12, 2018 | Posted by Team in Drug Discovery, New Innovations, Research |


Chandreyee Das, PhD, of Science Exchange recently spoke with Rajan Bawa, PhD, of CARE Research LLC, a leading preclinical CRO combining quality service for clients with excellent quality of life for animals — even for challenging or complex projects.

CD: Rajan, you’ve been in the pharmaceutical and biotechnology industry for over 40 years, can you tell us your company’s story?

RB: Twenty years ago, I started this histopathology company, Colorado Histo-Prep. In 2010, we acquired one of our preclinical CRO clients, which was CARE Research, enabling us to provide a one-stop-shop for our clients in the preclinical space.

CD: What capabilities does CARE Research have that set the company apart from other preclinical CROs?

RB: One differentiator is our ability to start projects very swiftly, with quick IACUC approval. We have extensive technical and regulatory experience.

Also, our responsiveness to our sponsor needs, being proactive in providing ongoing progress reports — we don’t wait until things go wrong.

We’re relatively small — we have about 20 people — but that means that we have high-ranking people in our organization — say, VP of Toxicology, or IACUC chairs — actively involved in projects. In large preclinical CROs, very often, there’s a study director who sits in his office, doesn’t even make it to the lab until the sponsor comes to visit.

CD: What preclinical services do you offer that are differentiated from other service providers?

RB: One area of strength is in DART (Developmental and reproductive toxicology) studies and ocular studies. DART services are not often offered by small or medium CROs, because they lack the expertise to carry out these specialized studies.

Ocular studies are another of our core competencies — these are also complex studies, you really have to know what you’re doing.

CD: What type of certifications does CARE Research hold?

RB: That’s a great question. We are OLA certified, AAALAC accredited, and we are GLP. We’re inspected regularly by FDA and USDA.

CD: What types of clients do you serve?

RB: We have a mix of different sponsors. We have large pharma, small biomedical companies, university researchers, startup companies.

In addition to our flexibility and ability to respond quickly, we have the ability to do very complex projects, especially in the surgical and ocular area in contrast to other CROs who may stay away from complex studies.

CD: Finally, could you describe your experience with Science Exchange?

RB: Science Exchange allows us to widen our reach, and allows us to find clients we would not have found using our internal resources. Also, the project managers whom I’ve interacted with are very helpful and responsive, and easily available to answer any questions, provide clarifications, etc in a patient manner.


Request a quote from CARE Research and get on the fastest path to completing your preclinical studies.

request quotes button


Science Exchange Announces Outsourced R&D Collaboration with UC Davis Venture Catalyst Group

February 12, 2018 | Posted by Team in Press Release |

Science Exchange Venture Catalyst Collaboration

Palo Alto, CA – February 12, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic collaboration with Venture Catalyst, a unit within the Technology Management and Corporate Relations division of the UC Davis Office of Research which supports the development of new ventures fueled by university research.

Science Exchange will provide entrepreneurs and startups participating in the Venture Catalyst Smart Toolkit for Accelerated Research Translation (START™) Program immediate access to the private R&D marketplace with dedicated PhD-level sourcing support around the clock and a special contracting structure to accelerate their research and development projects.

“The Science Exchange platform solves the challenges of R&D outsourcing by providing scientists with on-demand access to a diverse network of prequalified external providers under a single relationship while also providing sourcing departments with more information and control over their outsourcing spending,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be collaborating with Venture Catalyst to offer a customized R&D marketplace and help its portfolio of companies complete their research and clinical projects more quickly and efficiently. It’s clear that Venture Catalyst is supporting companies with extremely promising technologies in development, and we’re honored to help get their discoveries to market faster.”

With this collaboration, Science Exchange will support client-specific governance, approval workflows, and preferred vendors, all the while enabling instant access to research services and custom products from 2,500 providers in over 6,000 research areas. To help external service providers minimize the risk frequently associated with outsourcing,  Science Exchange’s guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by the best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated outsourced work.

Venture Catalyst is the latest innovation and startup support organization to choose to partner with Science Exchange. They now join more than 30 enterprise organizations including most of the top 20 biopharma companies that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for our startups to connect with a broad network of qualified scientific providers,” said Dushyant Pathak, Associate Vice Chancellor of Research and Executive Director of Venture Catalyst at UC Davis. “We anticipate that working with Science Exchange through the START Program will enable us to commercially advance the discoveries made by Venture Catalyst-supported startups and early-stage companies, in areas as diverse as biomedical and life sciences, agriculture and animal health, and physical sciences and engineering.”


About Venture Catalyst

Venture Catalyst furthers the University’s educational, research and public mission by supporting UC Davis students, faculty and researchers in translating science, engineering and innovative research through well-resourced startups, into societal impact.  Venture Catalyst engages collaboratively with internal and external drivers of innovation and works closely with the University’s Institute for Innovation & Entrepreneurship.  In addition to its Smart Toolkit for Accelerated Research Translation (START™) program, Science Translation and Innovative Research (STAIR™) Proof-of-Concept grants, Venture Catalyst supports a network of regional technology startup incubators through its Distributed Research Incubation & Venture Engine (DRIVE™) Network.

De Novo Antibody Sequencing with Isoleucine/Leucine Discrimination

February 9, 2018 | Posted by Team in Drug Discovery, New Innovations, Research |

A three-in-one solution for obtaining 100% accurate amino acid sequences for antibody proteins 
Innovation Highlight


Obtaining the sequence of monoclonal antibodies (mAbs) is crucial for the development of some novel biotherapeutics. However, the need to extensively characterize mAbs at the molecular level presents a unique challenge to drug developers and manufacturers. To address this difficulty, Bioinformatics Solutions, Inc. (BSI) has developed the proprietary de novo antibody protein sequencing technology, based on their PEAKS AB Software, to sequence antibodies

This de novo antibody sequencing service is a 3-in-1 solution for obtaining 100% accurate amino acid sequences for antibody proteins with unknown sequences. BSI combines state-of-the-art top-down and bottom-up mass spectrometry (MS) technologies to achieve high accuracy of the constructed sequence with amino acid-level confidence.

Discriminating isoleucine from leucine

The latest EThcD (electron-transfer/higher-energy collision dissociation) fragmentation scheme is incorporated into the bottom-up MS workflow. The rich MS/MS spectra derived from EThcD fragmentation not only improves the accuracy and sensitivity of de novo sequencing but also generates signature w-ion for direct discrimination of the isobaric amino acids, isoleucine, and leucine. In turn, from their bottom-up MS analysis, BSI derives the antibody protein sequences with isoleucine and leucine differentiation by the EThcD method.

Addressing antibody heterogeneity challenges

In addition, the top-down MS workflow focuses on the intact mass of light and heavy chains. This addresses the antibody heterogeneity issues such as C-terminal lysine truncation and glycan forms, which cannot be well answered by bottom-up methods. The top-down MS result can also further validate the bottom-up sequencing result.

By integrating bottom-up MS analysis with EThcD and top-down MS approaches, the de novo antibody sequencing with Ile/Leu differentiation service offered by BSI can guarantee 100% sequence accuracy.

Overall, the industry demands more extensive and accurate characterization of antibodies, and BSI strives to answer this call. With continuous improvement and optimization, BSI sets to provide the most robust next-generation protein sequencing. Learn more.

OnRamp Bioinformatics Partners with Science Exchange to Provide the Fastest Path to Interactive Genomic Analysis Services

February 8, 2018 | Posted by Team in Uncategorized |

OnRamp Bio Science Exchange

PALO ALTO, CA, February 07, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced the partnership with OnRamp BioInformatics, Inc. (OnRamp.Bio) to offer industry-leading bioinformatics services and tools to scientists around the globe.

Genomics big data and complex software analyses have historically required highly trained PhDs in bioinformatics using complicated command-line tools. OnRamp.Bio’s intuitive user interface, automated analyses and robust data management make it faster and easier for scientists, biologists, clinicians and other medical professionals to obtain interpretations of genomic data without the complexity of traditional deployments.

“IT and software complexity has stood in the way of progress for far too long. We’ve combined our deep knowledge of IT, software development and biology to provide intuitive, integrated systems and services that accelerate the mainstream adoption of NGS analyses within research, biotech and pharma,” said Tim Wesselman, CEO of OnRamp.Bio. “Genomic data is the currency of future medicine; there is nothing mankind has that is more valuable and we are excited to be working with Science Exchange to offer our support to researchers far and wide.”

OnRamp.Bio is a San Diego-based CRO and a leading provider of interactive genomic analysis. The company’s mission is to empower researchers, biologists and scientists with genomic answers and insights that they can understand and put to action. OnRamp.Bio has recently launched a new software-as-a-service for RNA-Seq and ChIP-Seq analysis, to meet the needs of researchers needing assistance in making decisions based on the large data sets yielded by these types of RNA and epigenetic experiments.

“We are excited to partner with OnRamp.Bio to provide the fastest path to interactive genomic analysis to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists have the services they need securely and readily available to aid their discoveries. OnRamp.Bio met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of genomics.”

About OnRamp BioInformatics, Inc.

OnRamp.Bio is a genomics software company providing bioinformatics analysis software and services, with cost-effective data management platforms for the computing and storage of genomic datasets. To learn more, visit their website or follow the company on Twitter @OnRampBio.

Novaseek Research Partners with Science Exchange to Broaden Access to Its CDNR Platform for Biomedical and Clinical Research

February 5, 2018 | Posted by Team in Drug Discovery, New Innovations, Press Release, Research |


PALO ALTO, Calif., DATE – Science Exchange, the world’s leading enterprise platform for outsourced research and development services and acquisition of human biospecimens, announced today its partnership with Novaseek Research Inc., a health information technology for life sciences company.

Now thousands of researchers using Science Exchange have on-demand access to Novaseek’s Clinical Data Network for Research (CDNR) platform to procure biospecimens, with patient consent and authorization, and associated real-world clinical data in pursuit of accelerating medical innovation. Researchers can utilize the CDNR platform in support of discovery, translational medicine, observational and clinical studies while Science Exchange manages the contracting process and tracks analytics to report performance and process improvement.

“Our CDNR platform can help accelerate the long and costly research process by precisely identifying patient populations with highly specific characteristics, starting early in the development process and continuing throughout,” said Andrei Soran, CEO of Novaseek Research. “Our partnership with Science Exchange enables clinical researchers to focus on getting medicines to market faster while Science Exchange provides operational and service support.”

“The fastest path to novel platforms like Novaseek’s CDNR via Science Exchange helps our leading biopharma clients to accelerate the drug development process and get important medicines to market quickly,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are committed to including the best scientific providers on our platform, and Novaseek meets our stringent vetting criteria. By leveraging population analytics, they help streamline study design and free scientists to focus on innovation.”

About Novaseek

Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit

About CDNR

Novaseek’s award-winning, novel, cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time. The CDNR enables researchers to define patient cohorts through population analytics and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies. CDNR enables the fulfillment of complex requests, such as the collection of biospecimens and data before and after specific treatments, without burdening patients with extra blood draws or extensive medical questionnaires. This approach allows more hospitals and patients to participate in supporting biomedical research.


Talk to the Novaseek team today about your biospecimen and clinical data needs — visit their storefront and request a quote with your Scope of Work.

Tech Q&A with Likarda, LLC

February 5, 2018 | Posted by Team in Drug Discovery, Research |

Guru Singh, Director of Scientific Content, recently spoke with Dr. Lisa Stehno-Bittel, President and Founder of Likarda LLC, an exciting biotech service company on the Science Exchange network.

GS: Nice to meet you, Lisa! Why do clients come to Likarda?

LSB: Likarda is the company you come to when your scientific questions require complex solutions. Our scientists work to create and validate novel assays on a number of different projects, in a timely and efficient manner.

GS: What capabilities does Likarda have that differentiate the company from other service providers and cell-based assay experts?

LSB: We have a strong portfolio of platform technologies that allow us to conduct assays that just aren’t available at other companies. First of all, we have a series of patents around generating, in a high throughput manner, 3D spheroids for drug screening, efficacy testing, toxicity testing, etc. Our Likarda CC Microplate is made using standard plate formats, but in each well of a 384-well plate are 150 different single microwells, in each of which we can grow a different spheroid. That way, we can reduce the number of replicates, saving time and money for the client.

GS: There are many different plate-based models on the market — organoplates, microfluidic chips, etc. — How do Likarda’s plates compare?

LSB: The difference is that Likarda’s plates are really made for a high throughput format and are ideal for complex experiments, for example, when you need to work with multi-cell-type 3D cultures, in an as natural environment as possible. Most of the time, we don’t use any sort of gel or matrix for the 3D cultures — the plates are low-adherence, so the cells stick to each other and not to the plate. This makes the plates easy to work with. We do have a patented hydrogel technology which allows us to make microencapsulated cells using biocompatible materials. We are the first to use these materials for microencapsulation. Microplates and hydrogel — these two technologies really set us apart.

GS: Very cool. How would you describe Likarda’s team?

LSB: All of our scientists have advanced Masters’ degrees in biology or physiology or PhD’s in physiology or bioengineering. We’re a relatively small team, so everyone is involved and gives input into these complex studies that we typically do.

GS: Your clients seem very diverse!

LSB: Yes! Our clients are in the pharmaceutical and nutraceutical industries, as well as food supplements and hygiene. We do work for multinational companies as well as smaller startups.

GS: How has Likarda grown over the years? What lies in the future?

LSB: We started Likarda 5 years ago with money from family and friends. Within 17 months, we were revenue-positive! We’re revenue-driven, and we’re working also on our own products — microplates, hydrogel, regenerative medicine therapies we’re getting ready to take to market.

GS: Can you talk about Likarda’s certifications?

LSB: We’re a woman-owned company, we have the capability to run GLP studies, and we can maintain GMP status for drug development projects, we have continual environmental monitoring.

GS: So, I take it, Likarda has had a successful experience being part of the Science Exchange network.

LSB: Definitely — Science Exchange has been wonderful to work with! With Science Exchange, you have a sourcing agent assigned to you from the very start. That person really does a good job of figuring out what the client needs, and matching them to the right CRO for their research.

Connect with the Likarda team to discuss your project today by visiting

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By